Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Pro-calcifying analysis of uraemic serum from patients treated with medium cut-off membrane in a prospective, cross-over study
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Protein bound drug removal by membranes of different albumin permeability
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Protein loss and medium cut-off haemodialysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Pruritus: Is there a grain of salty truth?
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Pushing the boundaries of hemodialysis: innovations in membranes and sorbents
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Pyrogen retention: Comparison of the novel medium cut-off (MCO) membrane with other dialyser membranes
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Quantification of Internal Filtration in Hollow Fiber Hemodialyzers with Medium Cut-Off Membrane
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Rationale for a New Classification of Solutes of Interest in Chronic Kidney Disease and Hemodialysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Rationale for Medium Cutoff Membranes in COVID-19 Patients Requiring Renal Replacement Therapy
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Reduction in all-cause hospitalization events seen in a randomized controlled trial comparing expanded hemodialysis vs. high-flux dialysis
Visit resource site
PD
Remote Automated Peritoneal Dialysis Management in Colombia - Bunch Alfonso, et al.
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.